Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nauman, D
Right arrow Articles by Cheitlin, M
Right arrow Search for Related Content
PubMed
Right arrow Articles by Nauman, D
Right arrow Articles by Cheitlin, M

Chest, Vol 102, 720-724, Copyright © 1992 by American College of Chest Physicians

ARTICLES

Effects of stopping long-term vasodilator therapy in patients with chronic aortic insufficiency

D Nauman, B Greenberg, B Massie, JD Bristow and M Cheitlin
Department of Medicine, Oregon Health Sciences University, Portland.

We studied the effects of stopping long-term vasodilator therapy in 17 patients with chronic stable aortic insufficiency. These patients received hydralazine for 37 +/- 15 months (mean +/- SD) and, as a result, had experienced a significant decrease in left ventricular volumes. All patients were followed clinically and ten of the patients underwent serial radionuclide evaluation at baseline, while receiving drug, and at 20 +/- 7 months after stopping drug therapy. No patient showed evidence of acute clinical deterioration when drug therapy was stopped. The rate of progression to valve replacement due to onset of symptoms or left ventricular dysfunction was not significantly different from that previously reported in a population with similar characteristics. Left ventricular size, however, returned to levels similar to baseline after drug therapy was stopped. We conclude that long-term vasodilator therapy may be discontinued in patients with chronic stable aortic insufficiency without causing clinical deterioration or significant alteration in rate of progression to valve replacement.


This article has been cited by other articles:


Home page
 NEJMHome page
A. Evangelista, P. Tornos, A. Sambola, G. Permanyer-Miralda, and J. Soler-Soler
Long-term vasodilator therapy in patients with severe aortic regurgitation.
N. Engl. J. Med., September 29, 2005; 353(13): 1342 - 1349.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American College of Chest Physicians.